
- Vol 40, Issue 4
The Whole Package
Key Takeaways
- A whole-body framework is emphasized to better manage psychiatric illness amid complex medical comorbidities and bidirectional organ-system effects.
- Clinical decision-making can be optimized when psychiatric pharmacotherapy is evaluated alongside cancer development, treatment course, and multidisciplinary input.
"It is amazing how much we know about the magnificent brain—and how much we have yet to learn."
PUBLISHER'S NOTE
As John J. Miller, MD, writes in this month’s editorial, it is amazing how much we know about the magnificent brain—and how much we have yet to learn. The same can be said of the human body as a whole, and how much we continue to learn not just about the individual organs and systems, but also how they interact and work together.
Psychiatry as a field has been a proponent of the whole-body approach for years, and many articles in our print issues and our website discuss the clinical implications of such.
In
Closer to home in the brain, this month’s
With that in mind, the editors at Psychiatric Times® have begun to reach out to their counterparts across MJH Life Sciences® in medical disciplines like eye care, dermatology, and internal medicine, to name a few. If there is an issue between psychiatry and another field you would like to read about, please let us know via [email protected].
In the meantime, both online at
Mike Hennessy Jr
President and CEO, MJH Life Sciences®
Articles in this issue
about 3 years ago
The Border Zone Between bvFTD and Primary Psychiatric Disordersabout 3 years ago
A Case of Clozapine and Cancerabout 3 years ago
On the Convergence of Science and Clinical Practiceabout 3 years ago
Role of Lithium in 2023 in Bipolar I Mania and Depressionabout 3 years ago
Professional Courtesy: Guidelines for Physiciansabout 3 years ago
Exploring the Biocognitive Modelabout 3 years ago
Toolsabout 3 years ago
Co-occurring Substance Use and Eating Disorders










